Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; cooperative research and development agreement with the United States Army for the preparation of Phase II clinical study for ISLA-101; and supply agreement with Catalent for the manufacture of Fenretinide softgels. Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.
Dr. Paul Donald Richard MacLeman M.B.A., MBA, BVSc, Grad Dip Tech, Grad Cert Eng, G